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Abstract 
Because of the more widespread and frequent use of cross-sectional techniques, mainly 
computed tomography (CT), an increasing number of adrenal tumors are detected as inci-
dental findings (“incidentalomas”). These incidentaloma patients are much more frequent than 
those undergoing imaging because of symptoms related to adrenal disease. CT and magnetic 
resonance imaging (MRI) are in most patients sufficient for characterization and follow-up of 
the incidentaloma. In a minor portion of patients, biochemical screening reveals a functional 
tumor and further diagnostic work-up and therapy need to be performed according to the 
type of hormonal overproduction. In oncological patients, especially when the morphological 
imaging criteria indicate an adrenal metastasis, biopsy of the lesion should be considered after 
pheochromocytoma is ruled out biochemically. In the minority of patients in whom CT and 
MRI fail to characterize the tumor and when time is of essence, functional imaging mainly by 
positron emission tomography (PET) is available using various tracers. The most used PET 
tracer, [
18F]fluoro-deoxy-glucose (
18FDG), is able to differentiate benign from malignant ad-
renal tumors in many patients. 
11C-metomidate (
11C-MTO) is a more specialized PET tracer 
that binds to the 11-beta-hydroxylase enzyme in the adrenal cortex and thus makes it possible 
to differ adrenal tumors (benign adrenocortical adenoma and adrenocortical cancer) from 
those of non-adrenocortical origin. 
Key words: Adrenal, Incidentaloma, Adenoma, Adrenocortical cancer, Positron emission tomog-
raphy, FDG, Metomidate, Computed tomography, Magnetic resonance imaging. 
Introduction 
Patients  who  present  with  clinical  symptoms 
from adrenal disease are rare compared to those who 
are diagnosed with an adrenal tumor when they un-
dergo  radiological  imaging,  usually  computed  to-
mography (CT), for other reasons than suspicion of 
adrenal  disease.  These  patients  who  are  diagnosed 
with  a  so-called  ”incidentaloma”  are  increasing  in 
parallel with the escalating use of cross sectional im-
aging by CT, magnetic resonance imaging (MRI) and 
ultrasonography (US). The work-up of the incidenta-
loma patient should aim at establishing whether the 
incidentaloma is functioning, i.e. hormonally active or 
not, and if the lesion is benign or malignant. 
The  detection  of  an  incidentaloma  requires  a 
clinical and biochemical work-up, usually performed 
by  an  endocrinologist,  and  the  radiologist  needs  to 
characterize  the  adrenal  mass  as  much  as  possible. 
The work-up must be governed by the situation for 
the  individual  patient.  For  example,  it  is  of  im-
portance if the patient has a present or earlier cancer 
diagnosis. Generally, in cancer patients the inciden-
taloma is malignant in about 30%, and even 50%, in 
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occasional reports, whereas in non-cancer patients the 
incidentaloma rarely is malignant. Also, the size of the 
tumor must be considered in this respect since the risk 
of malignancy increases with the diameter of the le-
sion. 
In  patients  with  functioning  incidentalomas  the 
management  needs  to  be  adopted  according  to  the 
symptoms and signs at presentation and the results of 
the biochemical and clinical work-up. Imaging usu-
ally  comprises  of  CT  or  MRI  to  detect  the  adrenal 
tumor  (for  example  adrenocortical  cancer,  pheo-
chromocytoma, Conn adenoma) or to localize an ex-
tra-adrenal  lesion  (pheochromocytoma,  paragangli-
oma). 
The decision on a surgical versus a non-surgical 
management  of  patients  with  a  non-functioning  inci-
dentaloma was previously governed primarily by the 
tumors size and all lesions larger than approximately 
4 cm were removed because of the risk of a malignant 
tumor.  Currently  this  decision  is  increasingly  influ-
enced by the imaging characterization of the inciden-
taloma.  When  an  adrenal  metastasis  is  suspected, 
core-needle biopsy or fine needle aspiration cytology 
may be more appropriate diagnostic procedure than 
further  imaging,  once  pheochromocytoma  has  been 
ruled out biochemically. 
This  review  examines  the  conventional  and 
novel imaging techniques available for the evaluation 
of  adrenal  tumors,  focusing  on  the  diagnosis  of 
adrenalcortical lesions. 
Radiological imaging 
In  the  imaging  evaluation,  conventional  mor-
phological characteristics need firstly to be assessed to 
indicate whether the incidentaloma is benign or ma-
lignant. Radiographic features which likely support a 
benign tumor include rounded, well delineated tumor 
borders,  clear  separation  of  the  tumor  from  sur-
rounding structures, no evidence of tumor extension 
into adjacent organs and homogenous internal struc-
ture. 
 The existence of areas of macroscopic fat, typically 
measuring -100 Hounsfield units (HU) at CT, is char-
acteristic of a myelolipoma comprising haematopoetic 
tissue  and  fat.  The  variation  in  this  regard  may  be 
considerable and macroscopic fat may constitute al-
most the whole a myelolipoma or merely appear as 
minimal “islands” within the mass. 
Because of the abundance of cytoplasmatic fat in 
benign adrenocortical tumors, most of these lesions 
may be characterized as such by simple attenuation 
measurement of the tumor in non-contrast enhanced 
CT  examination.  The  attenuation  of  the  normal 
parenchymal  organs  measures  approximately  30-70 
HU and the presence of cytoplasmatic fat decreases 
the attenuation of the tumor accordingly. This may be 
compared to the reduction of the hepatic attenuation 
at CT seen in patients with liver steatosis. Because the 
initial CT, at which the incidentaloma was diagnosed, 
usually  was  intravenously  contrast-enhanced,  the 
imaging work-up in the incidentaloma patient gener-
ally  necessitates  a  new  CT  examination.  This  dedi-
cated examination protocol of the adrenals generally 
comprise a pre-contrast CT, to allow for attenuation 
measurement,  scanning  in  the  venous  con-
trast-enhancement phase (90-120 seconds after injec-
tion  start)  and  a  delayed  examination  at  10  or  15 
minutes (depending on the local practice). 
Incidentalomas which at CT appear morpholog-
ically benign and measure ≤10HU in the pre-contrast 
CT examination can be diagnosed as a benign adre-
nocortical  adenoma  with  98-99%  specificity  (1-2). 
According  to  Swedish  National  guidelines  benign 
adrenocortical adenomas measuring less than 3-4 cm 
in  transaxial  diameter  generally  require  no  further 
imaging or radiological follow-up but the routines in 
this respect varies in different countries. In order not 
to  misdiagnose  a  simple  cyst  (attenuation  approxi-
mately 0-15 HU) as a benign adrenocortical adenoma, 
it  should,  however,  be  confirmed  that  the  lesion  is 
contrast-enhancing.  Similarly,  there  is  generally  no 
need for further imaging in larger lesions >4 cm that 
are apparently benign, for example a myelolipoma or 
a cyst. An example of a benign adrenocortical tumor 
characterized by attenuation measurements at CT is 
shown in Figure 1. 
 
Figure 1: A transaxial CT image without contrast enhancement 
shows a 5 cm homogenous circumscribed well delineated tumor in 
the right adrenal. The attenuation in the tumor was measured by 
placing a circular region of interest (ROI) in three contiguous slices 
and resulted in a mean attenuation of minus 15 Hounsfield Units 
consistent with a benign adrenocortical adenoma. Theranostics 2012, 2(5) 
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Incidentalomas  with  a  pre-contrast  attenuation 
>10HU, may additionally be characterized depending 
on their degree of contrast-enhancement and wash-
out. This is based on the characteristics of malignant 
as opposed to benign tumors. Malignant tumors are 
generally  poorly  vascularized  and,  compared  to 
normal tissues, they have a larger interstitial space in 
which  there  is  a  high  pressure  impeding  the  con-
trast-enhancement and delaying the contrast medium 
wash-out. This is in distinction to the well vascular-
ized  benign  lesions  which  like  normal  organs  and 
tissues contrast-enhance rapidly and have a fast con-
trast  medium  wash-out.  The  degree  of  con-
trast-enhancement and wash-out is based on the at-
tenuation measurements of the incidentaloma in the 
pre-contrast  (unenhanced,  U),  contrast-enhanced 
(enhanced, E) and delayed (D) phases. The “absolute 
wash-out” can be calculated thus: 
(E-D) / (E-U) 
Depending on whether the investigators, in the 
various  published  studies,  have  performed  the  de-
layed scanning at 10 or 15 minutes they apply differ-
ent  threshold  values  for  the  resulting  quotient  to 
which  the  result  in  the  individual  patient  can  be 
compared  and  these  “cut-off”  values  also  vary  de-
pending  on  the  local  expertise.  In  the  daily  clinical 
setting, an “absolute wash-out” based on a 15 minutes 
delayed examination < 0,6 indicates that the adrenal 
tumor may be malignant and > 0,6 that the lesion is 
probably benign (3-6). The sensitivity to differentiate 
malignant from benign incidentalomas ranges in the-
se studies ranges 79-89% and the specificity 87-96%. 
Also, a ”relative washout” can be applied when there 
is no pre-contrast examination and is calculated as: 
(E-D) / E. At a threshold value of 0,4 the sensitivity in 
these  studies  ranges  82-96%  and  the  specificity 
92-100%. When using a 0,5 threshold value the sensi-
tivity ranges 87-97% and the specificity 98-100% for 
differentiating the benign from the malignant adrenal 
tumors. 
When interpreting the results of the these con-
trast medium wash-out calculations it is important to 
realise that the attenuation measurements may vary 
depending  on  technical  parameters  such  as  partial 
volume effects, especially if the incidentaloma is small 
and thin sections have not been reconstructed. Also, 
there  are  operator  dependent  factors  to  consider, 
mainly how the regions of interest (ROIs) for attenua-
tion measurements are drawn and positioned. More-
over, factors related to maintenance such as calibra-
tion  of  the  CT  scanner,  is  of  importance  to  acquire 
reliable attenuation measurements. 
The impact of the “absolute wash-out” result on 
the  patient  management  varies  between  centres.  In 
some departments, a quotient > 0,6 in previously un-
characterized  incidentaloma  with  a  pre-contrast  at-
tenuation >10HU may be taken as evidence that the 
lesion is benign and that further imaging is unneces-
sary. In other centers, the result is interpreted differ-
ently. Thus, to confirm or rule out the malignant na-
ture of incidentalomas with a pre-contrast attenuation 
>10HU, radiological follow-up may be performed to 
measure any size change of the lesion and the result of 
the  “absolute  wash-out”  may  in  some  departments 
merely indicate whether this should be done at 3 or 6 
months after the time point when the incidentaloma 
was first detected. 
When time is of essence, MRI can be tried in or-
der to visualize microscopic fat in at least some of the 
incidentalomas  with  a  pre-contrast  attenuation 
>10HU at CT. MRI of the adrenals is performed in-
cluding  signal  sequences  “in  phase”  and  “out  of 
phase” (7-8). In a benign adrenocortical adenoma, the 
protons in the mixture of microscopic fat and water 
within the cytoplasm will add to the signal intensity 
(in phase) in the image and will also counteract and 
decrease the signal (out of phase) in the image. Other 
tumors do not demonstrate, however, this so-called 
“chemical shift” phenomenon; some benign adreno-
cortical adenomas with a low concentration of fat - the 
so called “lipid-poor adenomas” - will escape charac-
terization. As an alternative, especially in the young 
patients in whom one needs to consider the radiation 
dose, MRI is advantageous for follow-up of the tumor 
size when at the same time “in- and out of phase im-
aging” may be included in order to characterize the 
lesion if possible. A limitation in this respect are small 
tumors for which CT is generally preferred because of 
the better spatial resolution. 
Nuclear Medicine Imaging 
The imaging work-up and follow-up is for most 
incidentalomas adequately managed by CT and MRI. 
For a minority of these tumors further characteriza-
tion is, however, advantageous and for these patients 
there  are  several  molecular  imaging  techniques 
available. 
131I-norcholesterol (NP-59) scintigraphy 
131I-norcholesterol (NP-59) is no longer available 
in most European countries since the production of 
the  tracer  has  been  terminated.  It  was  previously 
primarily  used  for  scintigraphy  including  single 
photon emission computed tomography (SPECT) for 
preoperatively  localization  of  aldosterone  secreting 
adrenocortical  tumors  (Conn  adenomas)  in  primary 
hyperaldosteronism (9).  Theranostics 2012, 2(5) 
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Currently,  hypertensive  patients  with  a  bio-
chemical  diagnosis  of  primary  hyperaldosteronism 
instead undergo lateralisation of the Conn adenoma 
by  selective  venous  sampling  and  subsequent  hor-
monal  analysis.  A  finding  of  an  adrenal  tumor  at 
morphological  imaging  does  not  alone  suffice  for 
preoperative  localization  because  in  occasional  pa-
tients this adenoma is non-secreting and a very small 
Conn adenoma is instead harbored in the contra lat-
eral adrenal. 
Positron emission tomography of adrenal tu-
mors 
Positron  emission  tomography  (PET)  using 
[18F]fluoro-deoxy-glucose (18FDG) has developed as a 
powerful  molecular  imaging  technique,  mainly  in 
oncological patients, and is today regularly combined 
with  CT  (PET/CT)  to  also  acquire  a  morphological 
reference  to  the  functional  image  findings  and  vice 
versa.  The  use  of  18FDG  for  oncological  PET/CT  is 
based on its accumulation to a higher extent in ma-
lignant compared to benign tumors and most normal 
tissues, except the brain.  There is also a high accu-
mulation of 18FDG in kidney since it is excreted into 
the  urine  and  high  radioactivity  concentrations  are 
found in the urinary collective system and bladder. 
18FDG-PET/CT is mainly used in oncology for tumor 
characterization, staging, detection of current disease 
and  therapy  monitoring  and  is  well  established  in 
lung cancer, lymphoma, colorectal cancer and mela-
noma. 
18FDG-PET for characterization of adrenal 
tumors 
18FDG-PET and  18FDG-PET/CT have also been 
used for adrenal imaging in several studies to differ-
entiate  benign  from  malignant  tumors  (10-24).  For 
patients in whom the incidentaloma comprises a me-
tastasis 18FDG-PET/CT may be useful, to detect other 
metastases and to find the primary tumor when this 
has not previously been diagnosed. Also in adreno-
cortical cancer,  18FDG-PET/CT can be used for stag-
ing of the disease. 
In  the  image  reading,  evaluation  of  the  18FDG 
uptake in various organs and tissues is generally as-
sessed  visually.  To  facilitate  the  PET  image  evalua-
tion,  measurements  of  the  18FDG  uptake  in  tumors 
and normal organs are regularly performed and often 
the  liver  is  used  as  a  normal  tissue  references.  The 
rational for calculating the tumor-to-liver ratio is that 
malignant  lesions  generally  exhibit  a  higher  18FDG 
uptake than that of the liver. 
Many  previously  published  studies  that  have 
applied  18FGD-PET and  18FDG-PET/CT to differ be-
nign  from  malignant  adrenal  tumors  have  been  in-
cluded  in  a  recent  systematic  review  and  me-
ta-analysis (24). This comprises 21 studies published 
1995-2009 including 1391 lesions (824 benign and 567 
malignant) in 1217 patients. The mean sensitivity to 
differentiate a malignant from a benign adrenal lesion 
was (95% Confidence Interval, CI) 0,97 (0,93-0,98) and 
the specificity was 0,91 (0,87-0,94). The results were 
similar  when  18FDG-PET  and  18FDG-PET/CT  was 
used. The various image evaluation techniques that 
had been applied to differentiate benign from malig-
nant  adrenal  lesions  such  as  visual  analysis,  meas-
urements  of  tumor  uptake  of  18FDG  or  tu-
mor-to-normal tissue uptake ratios were equally effi-
cient. 
One large 18FDG-PET study published after this 
meta-analysis that is worthy of mentioning aimed at 
differing benign from malignant adrenal tumors in 81 
cancer  patients  by  using  the  adrenal  tumor-to-liver 
ratio.  A  cut-off  value  of  1,8  for  the  adrenal  tu-
mor-to-liver ratio corresponded to 87% sensitivity and 
91% specificity whereas a cut-off value of 1,68 corre-
sponded  to  90%  sensitivity  and  91%  specificity  (2). 
However, the inherent problem in using uptake rati-
os, such as the adrenal tumor-to-liver ratio, is that the 
specificity in this assessment is impaired by the fact 
that some benign adrenal lesions also demonstrate a 
moderate to high  18FDG uptake, such as benign and 
malignant pheochromocytomas that generally have a 
moderate to high 18FDG uptake (25-26). 
18FDG-PET imaging of adrenocortical cancer 
A  French  study  on  18FDG-PET/CT  imaging  of 
adrenocortical cancer (ACC) included 28 patients (27). 
The results of 18FDG-PET/CT were correlated to those 
at CT that was performed separately. The reason for 
this was that the CT examination performed in con-
junction with PET  was used merely for attenuation 
correction  and  anatomical  correlation  of  the  PET 
findings  and  had  been  carried  out  without  intrave-
nous  contrast-enhancement  using  reduced  radiation 
dose. For 18FDG-PET/CT the lesion based sensitivity 
and specificity was 90% and 93%, respectively, and 
the corresponding figures for CT was 88% and 82%. 
Interestingly, 12% of the lesions were diagnosed only 
by18FDG-PET/CT  and  10%  only  by  CT.  In  the  pa-
tient-based analysis, the methods were concordant in 
25  patients  and  showed  95%  sensitivity  for  both 
18FDG-PET/CT and CT and 83% and 100% specificity, 
respectively. Thus, in only three patients the methods 
were discordant.18FDG-PET/CT was false positive in 
one patient that  was true  negative by  CT, depicted 
recurrent tumor in one patient that was missed by CT 
and missed a liver lesion that was diagnosed by CT. In Theranostics 2012, 2(5) 
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a  smaller  study  twelve  patients  underwent 
18FDG-PET to assess recurrent or metastatic adreno-
cortical cancer the sensitivity was 83% (28). In two of 
the patients, small lung metastases and a liver metas-
tasis, respectively, escaped detection. 
11C-metomidate-PET for characterization of 
adrenal tumors 
Etomidate (ETO) has been used as an anesthetic 
agent in veterinary medicine. Metomidate (MTO) is 
the methyl-ester of etomidate and both are inhibitors 
of the CYP11B enzymes 11β-hydroxylase (CYP11B1, 
P45011β)  and  aldosterone  synthase  (CYP11B2, 
P450aldo) that are involved in the cortisol and aldos-
terone synthesis, respectively. Based on the high af-
finity to these enzymes and the consequently specific 
adrenocortical  binding  properties,  ETO  and  MTO 
have been labeled with  11C and 18F and used as PET 
tracers  for  adrenal  imaging.  In  the  first  report  on 
11C-MTO  and  11C-ETO  their  binding  capacity  was 
investigated by frozen section autoradiography using 
adrenal  cortical  tissue  from  different  species.  The 
binding of both 11C-MTO and 11C-ETO was high and 
specific and was confirmed in vivo by PET imaging in 
monkeys. In the first clinical study (29) 11C-MTO was 
chosen as the tracer because of the better radiochem-
ical  characteristics.  In  this  study,  15  patients  with 
various adrenal masses underwent 11C-MTO-PET. All 
tumors  of  adrenocortical  origin  (6  adenomas,  1  hy-
perplasia,  2  adrenocortical  cancers)  showed  a  high 
11C-MTO  uptake  and  were  unequivocally  distin-
guished from the non-cortical lesions (1 myelolipoma, 
1  pheochromocytoma,  1  metastasis,  1  mesenchymal 
tumor and 2 cysts) that were devoid of tracer uptake. 
11C-MTO uptake was found in the  normal adrenals 
and in the stomach high radioactivity concentration 
appeared  in  the  gastric  juice  into  which  the  tracer 
and/or its metabolites are transported. 
Interestingly, also for 18FDG a large variation in 
tracer  uptake  in  adrenocortical  cancer  has  been  re-
ported in a prospective study of 77 patients with ad-
renal  incidentalomas  that  included  22  subjects  with 
adrenocortical  cancer  (30)  and  in  two  studies  PET 
using 11C-MTO and 18FDG have been compared in the 
same  patients  (31-32).  In  19  patients  with  various 
types of adrenal lesions (10 benign cortical adenomas, 
2  phaeochromocytomas,  1  adrenocortical  cancer,  3 
malignant  non-cortical  tumors,  1  lipoma,  1  cyst,  1 
normal adrenal) 11C-MTO accumulated in all tumors 
of adrenocortical origin and 18FDG-PET detected 2/3 
malignant  tumors  whereas  the  benign  lesions  were 
difficult to visualize or not seen at all (31). In 16 pa-
tients  with  a  mixture  of  adrenal  tumors  (1  adrenal 
metastasis,  1  adrenocortical  cancer,  1  malignant 
phaeochromocytoma, 10 adenomas, 1 hyperplasia, 2 
benign phaeochromocytomas) 11C-MTO-PET differed 
the  adrenocortical  tumors  from  those  of 
non-adrenocortical origin  and  18FDG-PET differenti-
ated the malignant from the benign tumors (32).  
The largest study to date on 11C-MTO-PET com-
prised  73  patients  with  75  adrenal  tumors  (26  ade-
nomas,  13  adrenocortical  cancers,  8  hyperplasia,  6 
pheochromocytoma,  3  metastases,  19  tumors  of 
non-adrenal  origin)  in  a  wide  size  range  of  1-20cm 
(33). By applying a strict correlation of the PET find-
ings with the histopahological diagnosis, 89% sensi-
tivity and 96% specificity was determined in distin-
guishing adrenocortical from the non-adrenocortical 
lesions. Three tumors that all had a diameter ≤1cm, 
were missed and led to the lower sensitivity in this 
study  than  in  previous  reports.  Measurements  of 
11C-MTO adrenal tumor uptake were correlated to the 
histopahological  findings.  The  PET  measurements 
could, however, not distinguish the benign from the 
malignant  adrenocortical  tumors  but  with  a  tu-
mor-to-normal (contralateral)-adrenal ratio >1,4 there 
was a 99,5% risk of an adrenocortical tumor (adenoma 
or cancer). 
The role of 11C-MTO-PET in comparison with CT 
and MRI was tested in the clinical setting for the im-
aging  work-up  of  44  adrenal  incidentalomas  in  38 
patients  (34).  Morphological  imaging  proved  suffi-
cient for all but a few patients in whom CT and MRI 
failed  to  characterize  the  tumor  but  where 
11C-MTO-PET  added  information  by  defining  the 
adrenocortical  or  non-adrenocortical  origin  of  the 
lesion. 
The role of  11C-MTO-PET in patients with pri-
mary  hyperaldosteronism  was  investigated  in  two 
studies (35-36). Nine patients with small Conn ade-
nomas (average 1,7 cm; range 1-2,5 cm) were exam-
ined and then re-examined after three days of per oral 
dexametasone medication. For matters of comparison, 
two  patients  with  non-functioning  adrenocortical 
adenomas were included into the study. The tumor 
visibility was similar in both examinations and, alt-
hough the tumor-to-normal-adrenal ratios were lower 
in  the  post-treatment  examinations,  this  difference 
was not statistically significant. It was hypothesized 
that  corticoid  treatment  decreases  ACTH  secretion 
and thereby the 11beta-hydroxylase concentrations in 
normal adrenal parenchyma but not in Conn adeno-
mas. The expected increase of the tumor-no-normal 
tissue contrast should thereby facilitate detection of 
small Conn adenomas. This hypothesis could, how-
ever, not be verified (35). In a further attempt to im-
prove  the  image  contrast,  principal  compartment 
analysis  (PCA)  was  applied  to  11C-MTO-PET  from Theranostics 2012, 2(5) 
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seven patients who were examined according to the 
same  protocol  before  and  after  dexametasone  treat-
ment (36). By PCA it was possible to isolate separate 
image volumes, representing the early, intermediate 
and late pharmacokinetic phases of 11C-metomidate in 
these dynamic examinations performed 0-45 minutes 
after tracer injection. The Conn adenomas were best 
depicted in the PCA component that represented the 
intermediate  11C-MTO  pharmacokinetics.  In  this 
component the image noise decreased and the tissue 
contrast  improved.  No  firm  conclusions  could  be 
drawn  regarding  the  effect  of  dexametasone  treat-
ment on the 11C-MTO uptake in Conn adenomas and 
normal adrenals. 
 
 
 
Figure  2:  A  transaxial  PET/CT  fusion  image  with 
11C-metomidate in a patient with recurrent disease from a pre-
viously resected adrenocortical cancer. A high focal tracer uptake 
is seen in a liver metastasis. 
 
11C-metomidate-PET in adrenocortical cancer 
In a study concentrated exclusively on adreno-
cortical carcinoma patients 13 11C-MTO examinations 
were performed in 11 subjects and correlated to CT, 
findings  at  surgery,  autopsy  and  histopathological 
together  with  clinical  follow-up  (37).  11C-MTO-PET 
visualized all viable tumors with high tracer uptake, 
and revealed two more lesions compared to CT. Three 
necrotic tumors, detected by CT were detected as false 
negative observations by 11C-MTO-PET, as confirmed 
at surgery and histopathological examination. A true 
negative observation was obtained at PET in the case 
of a suspected liver metastasis at CT. The  11C-MTO 
uptake was higher in tumors than in normal adrenal 
and  liver.  11C-MTO-PET  performed  in  connection 
with medication that could potentially affect the trac-
er uptake, such as adrenal steroid inhibitors (metap-
yrone,  ketoconazole)  and  chemotherapy  (streptozo-
cin, p’-DDD, 5-FU), resulted in lower uptake in viable 
tumors and in normal tissues, for example liver and 
normal adrenal, compared to examinations executed 
when the patients were without such treatment. An 
example  of  metastastic  adrenocortical  cancer  diag-
nosed by 11C-MTO-PET/CT is illustrated in Figure 2. 
Conclusion 
In most patients, CT and MRI are sufficient for 
characterization  and  follow-up  of  adrenal  tumors. 
Functional  imaging  by  PET  with  18FDG-PET  and 
11C-MTO may be used as problem solving tools when 
CT and MRI fail. In centers where this technique is 
available,  11C-MTO-PET/CT  is  currently,  used  also 
preoperatively in patients with suspected adrenocor-
tical cancer and for follow-up and detection of recur-
rent disease. 
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